Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 707 of 6351
-
New combo aims to stall prostate cancer spread
Disease control Recruiting nowThis study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New eye drug aims to cut injection frequency for wet AMD patients
Disease control OngoingThis is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could less radiation be enough? new trial hopes to reduce side effects for kids with brain tumors
Disease control Recruiting nowThis phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and …
Phase 2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for kids with rare blood vessel disease: avacopan trial launches
Disease control OngoingThe main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New antibody combo tackles tough leukemia
Disease control Recruiting nowThe planned trial offers treatment cohorts for patients with full cytologic relapse (R/R ALL - Cohort 1), as well as for patients with molecular failure/relapse (MRD+ ALL - Cohort 2). Basically, the study aims to develop data for optimization of first-line therapy of T-ALL, eithe…
Phase 2 • Sponsor: Goethe University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Sound waves open brain barrier to attack deadly tumor
Disease control PausedThis will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) i…
Phase 1/2 • Sponsor: NaviFUS Corporation • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
Radioactive therapy targets stubborn leukemia in early trial
Disease control OngoingCXCR4 inhibition may represent a new therapeutic strategy in acute leukemia (AL) patients, not only by increasing chemosensitivity but also by preventing relapse of the disease by disruption of the interaction of residual leukemic cells with the bone marrow niche. Radiolabeled CX…
Phase 1/2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for babies with severe epilepsy: fenfluramine safety trial launches
Disease control Recruiting nowDravet syndrome is a genetic epilepsy associated with pathogenic variants in SCN1A that codes for Nav1.1, a protein necessary for sodium channels. Children with Dravet syndrome classically present in the first year of life with prolonged seizures, often hemiclonic and in the sett…
Phase 4 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo aims to supercharge weight loss in obesity trial
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a second ADC tame breast cancer after the first fails?
Disease control Recruiting nowThis is a prospective, open-label, phase 2 platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Mpox vaccine trial expands to children: a step toward broader protection
Vaccine OngoingAll participants will receive 2 vaccinations of the same dose of Modified Vaccinia Ankara Virus (MVA-BN) vaccine 4 weeks apart (standard regimen). Serum samples for assessment of immune response will be collected at baseline (visit of first vaccination) and at 2 weeks (week 6), …
Phase 2 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Jun 27, 2026 07:59 UTC
-
A tailored group program aims to shield migrant mothers from depression and anxiety
Prevention CompletedThis pilot randomized controlled trial will test a theory-based, trauma-informed, and culturally-tailored intervention \[Mama Empoderada' (Mom Power)\] to promote mental health and positive parenting among migrant mothers with young children.
Sponsor: San Diego State University • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Head-to-Head: which drug works better for psoriatic arthritis?
Disease control CompletedThe purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could less chemo be enough? new trial tests shorter treatment for head and neck cancer
Disease control Recruiting nowThis is a phase II, prospective, non-randomized, single-arm, multicentric study to evaluate the activity and safety of treatment with 4 cycles (instead of 6) of chemotherapy (platinum (cisplatin or carboplatin) and 5-Fluorouracil) in combination with pembrolizumab for the first-l…
Phase 2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Could a daily antibiotic stop a deadly hospital infection?
Prevention Recruiting nowThe goal of this clinical trial is to determine if oral vancomycin can prevent C.diff infection in adults who are critically ill and are at high risk of C.diff infection due to their medical conditions and being in the hospital. It will also help us learn about the safety of the …
Phase 2/3 • Sponsor: Riverside University Health System Medical Center • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
Could a rheumatoid arthritis drug ease long COVID brain fog?
Disease control Recruiting nowThe overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom…
Phase 3 • Sponsor: Wes Ely • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Lung cancer vaccine trial aims to stop tumors from coming back
Disease control Recruiting nowThe goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help p…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can donor immune cells help fight pancreatic cancer after surgery?
Disease control Recruiting nowThis is a phase I/II study which intends to characterize the safety, tolerability, and preliminary efficacy of Allogeneic Magicell-NK infusion in PDA or cholangiocarcinoma patients after surgery. Subjects will receive a total of 6 intravenous (IV) infusions of the IP on the 11th …
Phase 1/2 • Sponsor: Medigen Biotechnology Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control OngoingPfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy w…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Inhaled drug offers new hope for stubborn lung infection
Disease control Recruiting nowTreatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression. The outcome of these patients is poor, and treatment is very long. Indeed, this duration is base…
Phase 2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC